<?xml version='1.0' encoding='utf-8'?>
<document id="24996374"><sentence text="Clinical pharmacology of deferasirox."><entity charOffset="25-36" id="DDI-PubMed.24996374.s1.e0" text="deferasirox" /></sentence><sentence text="Iron accumulation is a consequence of regular red cell transfusions, and can occur as a result of ineffective erythropoiesis secondary to increased intestinal iron absorption, in patients with various anemias"><entity charOffset="0-4" id="DDI-PubMed.24996374.s2.e0" text="Iron" /><entity charOffset="159-163" id="DDI-PubMed.24996374.s2.e1" text="iron" /><pair ddi="false" e1="DDI-PubMed.24996374.s2.e0" e2="DDI-PubMed.24996374.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24996374.s2.e0" e2="DDI-PubMed.24996374.s2.e1" /></sentence><sentence text=" Without appropriate treatment, iron overload can lead to increased morbidity and mortality"><entity charOffset="32-36" id="DDI-PubMed.24996374.s3.e0" text="iron" /></sentence><sentence text=" Deferasirox is an oral iron chelator effective for reduction of body iron in iron-overloaded patients with transfusion-dependent anemias and non-transfusion-dependent thalassemia, with a well-established safety profile"><entity charOffset="1-12" id="DDI-PubMed.24996374.s4.e0" text="Deferasirox" /><entity charOffset="24-28" id="DDI-PubMed.24996374.s4.e1" text="iron" /><entity charOffset="70-74" id="DDI-PubMed.24996374.s4.e2" text="iron" /><entity charOffset="78-82" id="DDI-PubMed.24996374.s4.e3" text="iron" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e0" e2="DDI-PubMed.24996374.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e0" e2="DDI-PubMed.24996374.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e0" e2="DDI-PubMed.24996374.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e0" e2="DDI-PubMed.24996374.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e1" e2="DDI-PubMed.24996374.s4.e1" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e1" e2="DDI-PubMed.24996374.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e1" e2="DDI-PubMed.24996374.s4.e3" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e2" e2="DDI-PubMed.24996374.s4.e2" /><pair ddi="false" e1="DDI-PubMed.24996374.s4.e2" e2="DDI-PubMed.24996374.s4.e3" /></sentence><sentence text=" This review summarizes the clinical pharmacokinetics, pharmacodynamics, and drug-drug interaction profile of deferasirox, and the claims supporting once-daily dosing for effective chelation"><entity charOffset="110-121" id="DDI-PubMed.24996374.s5.e0" text="deferasirox" /></sentence><sentence text=" Sustained labile plasma iron suppression is observed with no rebound between doses, protecting organs from potential tissue damage"><entity charOffset="25-29" id="DDI-PubMed.24996374.s6.e0" text="iron" /></sentence><sentence text=" Increased iron excretion positively correlates with increased deferasirox exposure; to optimize iron removal transfusional iron intake, body iron burden and safety parameters should also be considered"><entity charOffset="11-15" id="DDI-PubMed.24996374.s7.e0" text="iron" /><entity charOffset="63-74" id="DDI-PubMed.24996374.s7.e1" text="deferasirox" /><entity charOffset="97-101" id="DDI-PubMed.24996374.s7.e2" text="iron" /><entity charOffset="124-128" id="DDI-PubMed.24996374.s7.e3" text="iron" /><entity charOffset="142-146" id="DDI-PubMed.24996374.s7.e4" text="iron" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e0" e2="DDI-PubMed.24996374.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e0" e2="DDI-PubMed.24996374.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e0" e2="DDI-PubMed.24996374.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e0" e2="DDI-PubMed.24996374.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e0" e2="DDI-PubMed.24996374.s7.e4" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e1" e2="DDI-PubMed.24996374.s7.e1" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e1" e2="DDI-PubMed.24996374.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e1" e2="DDI-PubMed.24996374.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e1" e2="DDI-PubMed.24996374.s7.e4" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e2" e2="DDI-PubMed.24996374.s7.e2" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e2" e2="DDI-PubMed.24996374.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e2" e2="DDI-PubMed.24996374.s7.e4" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e3" e2="DDI-PubMed.24996374.s7.e3" /><pair ddi="false" e1="DDI-PubMed.24996374.s7.e3" e2="DDI-PubMed.24996374.s7.e4" /></sentence><sentence text=" Deferasirox dispersible tablets should be taken ≥30 min before food due to an effect of food on bioavailability"><entity charOffset="1-12" id="DDI-PubMed.24996374.s8.e0" text="Deferasirox" /></sentence><sentence text=" Dosing is consistent across pediatric and adult patients and there is no ethnic sensitivity" /><sentence text=" Dose adjustment is required for patients with hepatic impairment and may be considered upon coadministration with strong uridine diphosphate glucuronosyltransferase inducers or bile acid sequestrants (coadministration should be avoided where possible), and patients should be monitored upon coadministration with cytochrome P450 (CYP) 3A4/5, CYP2C8, or CYP1A2 substrates"><entity charOffset="122-141" id="DDI-PubMed.24996374.s10.e0" text="uridine diphosphate" /><entity charOffset="178-187" id="DDI-PubMed.24996374.s10.e1" text="bile acid" /><pair ddi="false" e1="DDI-PubMed.24996374.s10.e0" e2="DDI-PubMed.24996374.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24996374.s10.e0" e2="DDI-PubMed.24996374.s10.e1" /></sentence><sentence text=" Coadministration with hydroxyurea, a fetal hemoglobin modulator, does not appear to impact deferasirox pharmacokinetics"><entity charOffset="23-34" id="DDI-PubMed.24996374.s11.e0" text="hydroxyurea" /><entity charOffset="92-103" id="DDI-PubMed.24996374.s11.e1" text="deferasirox" /><pair ddi="false" e1="DDI-PubMed.24996374.s11.e0" e2="DDI-PubMed.24996374.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24996374.s11.e0" e2="DDI-PubMed.24996374.s11.e1" /></sentence><sentence text=" In summary, a substantial body of clinical and pharmacokinetic data are available for deferasirox to guide its optimal use in multiple patient populations and clinical circumstances"><entity charOffset="87-98" id="DDI-PubMed.24996374.s12.e0" text="deferasirox" /></sentence><sentence text=" " /></document>